Publications by authors named "D Touchette"
Climate change is predicted to alter the hydrological and thermal regimes of high-mountain streams, particularly glacier-fed streams. However, relatively little is known about how these environmental changes impact the microbial communities in glacier-fed streams. Here, we operated streamside flume mesocosms in the Swiss Alps, where benthic biofilms were grown under treatments simulating climate change.
View Article and Find Full Text PDFBackground: In the United States (US), hepatitis C virus (HCV) screening is not covered by payers in settings outside of primary care. A non-traditional, emergency department (ED)-based HCV screening program can be cost-effective and identify infection in vulnerable populations with a high HCV risk. This study examined the long-term cost-effectiveness of routine HCV screening and linkage-to-care for high-risk patients in the ED from the payer's perspective.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluated the cost-effectiveness of a pharmacist-led medication therapy management clinic (MTMC) for type 2 diabetes compared to usual care, using a simulation model that incorporated diabetes effects and complications.
- Results showed that MTMC had a total cost of $160,145 and 6.73 quality-adjusted life-years (QALYs), while usual care had costs of $152,806 and 6.65 QALYs, yielding an incremental cost-effectiveness ratio (ICER) of $93,375 per QALY gained, which is deemed cost-effective.
- The findings suggest that including clinical pharmacy services may enhance healthcare strategies and support broader reimbursement for such services to improve
Objectives: Adherence to medications is important for the management of chronic diseases. Although the proportion of days covered (PDC) is a common metric for measuring adherence, it may be insufficient to distinguish relevant differences in medication-taking behavior. Group-based trajectory models (GBTMs) have been used to better represent adherence over time.
View Article and Find Full Text PDFBackground: Eculizumab and efgartigimod were approved to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (anti-AChR Ab-positive gMG). These relatively new biological treatments provide a more rapid onset of action and improved efficacy compared with conventional immunosuppressive treatments, but at a higher cost.
Objective: To assess the cost-effectiveness of eculizumab and, separately, efgartigimod, each added to conventional therapy vs conventional therapy alone, among patients with refractory anti-AChR Ab-positive gMG and those with anti-AChR Ab-positive gMG, respectively.